Celltrion Unveils Strategy Amid Series Of Milestones

Korean Company Secures Italian Bids While Launching A Product In South Korea

South Korea’s Celltrion has doubled down on its efforts in further building its pipeline, eyeing a target of 22 commercialized products by 2030 while also aiming to submit INDs for 13 novel compounds.

South Korea flag waving against clean blue sky, close up, isolated with clipping path mask alpha channel transparency
To Bring In FDA Approved Mental Health Related Digital Therapeutics • Source: Shutterstock

More from Strategy

More from Generics Bulletin